These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6225762)

  • 1. Ceftazidime in patients with Pseudomonas infections.
    Eron LJ; Park CH; Hixon DL; Goldenberg RI; Poretz DM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():161-9. PubMed ID: 6225762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime therapy of serious bacterial infections.
    Eron LJ; Goldenberg RI; Park CH; Poretz DM
    Antimicrob Agents Chemother; 1983 Feb; 23(2):236-41. PubMed ID: 6340601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime in severe infections: a Swiss multicentre study.
    Francioli P; Clément M; Geroulanos S; von Graevenitz A; Luthy R; Regamey C; Stalder H; Vogt M; Waldvogel FA
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():139-46. PubMed ID: 6225761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime treatment in intensive care patients.
    van Dalen R; Muytjens HL; Gimbrère JS
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():189-97. PubMed ID: 6225763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime in the therapy of serious Gram-negative bacillary infections.
    Pottage JC; Karakusis PH; Fliegelman RM; Levin S; Trenholme GM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():223-8. PubMed ID: 6352623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR
    Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections.
    Clumeck N; Gordts B; Dab I; Jaspar N; Van Laethem Y; Butzler JP
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():207-11. PubMed ID: 6352620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.
    Maslow MJ; Rosenberg A; Pollock AA; Press RA; Silverman D; El-Sadr W; Richmond AS; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():213-7. PubMed ID: 6413486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime in clinical practice.
    Alestig K; Eilard T; Norrby R; Svensson R; Trollfors B; Brorson JE
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():111-4. PubMed ID: 6225759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open study of ceftazidime in serious infections due to multiply-resistant bacteria.
    Pechère JC; Delisle R
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():181-8. PubMed ID: 6352619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open study of the use of ceftazidime in Gram-negative infections.
    Wardle JK; Snow MH; Ingham HR; Selkon JB
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():389-93. PubMed ID: 6352650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced sensitivity to beta-lactam antibiotics arising during ceftazidime treatment of Pseudomonas aeruginosa infections.
    King A; Shannon K; Eykyn S; Phillips I
    J Antimicrob Chemother; 1983 Oct; 12(4):363-70. PubMed ID: 6417101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections.
    Mouton Y; Chidiac C; Humbert G; Leroy J; Veyssier P; Modai J; Bertrand A; Dellamonica P; Micoud M; Stahl JP
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():133-40. PubMed ID: 8150757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].
    Blaser J; Bauernfeind A; Vogt M; Lüthy R
    Dtsch Med Wochenschr; 1983 Sep; 108(35):1312-7. PubMed ID: 6411442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of ceftazidime in internal medicine in Japan.
    Shimada K
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():395-7. PubMed ID: 6225765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime: a new approach in the treatment of moderate and severe infections.
    Abbas AM; Taylor MC; Newby D; Jones RB; Rigby CC; Haste AR; Cantor AM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():147-52. PubMed ID: 6352615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of bone infections with ceftazidime.
    Dutoy JP; Wauters G
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():229-33. PubMed ID: 6352624
    [No Abstract]   [Full Text] [Related]  

  • 20. Ceftazidime therapy for serious infections.
    Bint AJ; Constable J; Patton KR; Constable FL
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():115-21. PubMed ID: 6352613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.